Linked Life Data

6673339

Source:http://linkedlifedata.com/resource/pubmed/id/6673339

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1984-5-24
pubmed:abstractText
Thirty patients with chronic obstructive pulmonary disease (ChOPD) and concomitant ischemic heart disease (IHD) were studied that were admitted to the clinic for the treatment of a recurrence of the basic disease within the period 1981-1982. The patients were grouped into three groups of 10 patients and each group was treated for a period of 14 days, as follows: group 1--10 patients were given only sectral 50 mg per os during the first week and 10 mg/day during the second week; group II--treated with falicard, 5 mg daily, intravenously, for one week and later 2 X 5 mg, intravenously--the second week; group III, received sectral--50-100 mg/day after 5 mg falicard intravenously. Best results, manifested with a reduction of the paroxysms of dyspnea and stenocardia, were obtained in group III, suggesting the advantage of the combined effect with cardioselective beta-blockers and Ca-antagonists in the patients with ChOPD and concomitant IHD.
pubmed:language
bul
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0506-2772
pubmed:author
pubmed:issnType
Print
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
86-9
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
1983
pubmed:articleTitle
[Use of Falicard and Sectral in patients with COPD and ischemic heart disease].
pubmed:publicationType
Journal Article, English Abstract